Retatrutide pen 4mg GLP3 (Triple G)

Triple G Retatrutide - what is this modern peptide

Triple G Retatrutide also known as GLP 3, is an innovative next-generation peptide designed as an advanced agonist of triple incretin receptors (GLP-1, GIP and GCGR). The substance represents the next stage in the development of metabolic and weight-loss therapies, combining the properties of three key hormones responsible for regulating appetite, glucose metabolism and energy burning. This makes it stand out significantly from earlier formulations such as semaglutide or tirzepatyd.

Triple G Retatrutide - mechanism of action

The mechanism of action of Triple G Retatrutide is based on simultaneous activation of three receptors:

• GLP-1 (glucagon-like peptide-1) - reduces appetite, slows gastric emptying and promotes insulin secretion.
• GIP (glucose-dependent insulinotropic peptide) - Improves cellular sensitivity to insulin and contributes to better energy utilization.
• GCGR (glucagon receptor) - Increases energy consumption and supports fat burning processes.

The combination of these three mechanisms produces a synergistic effect - more effective weight control, glucose stabilization and improved metabolic parameters.

Triple G Retatrutide - effects according to studies (scientific information)

The use of Retatrutide commonly known as GLP 3 in clinical trials has been associated with a number of effects:

• Significant weight reduction (average 20-25% in research of 2023),
• Improving blood sugar control,
• Reduction in cravings and frequency of snacking,
• Improving lipid profile (lowering triglycerides and LDL cholesterol),
• Increase energy expenditure and speed up metabolism.

Thanks to its triple mechanism, Retatrutide shows a much more potent effect than classic GLP-1 analogs, making it one of the most promising peptides for the treatment of obesity and metabolic syndrome.

Retatrutide vs Tirzepatide (scientific data)

Thiothiazepatide, which is a dual agonist (GLP-1/GIP), has already revolutionized the treatment of obesity. However, Retatrutide adds a third element - receptor activation glucagon (GCGR).
It causes:

• Stronger stimulation of fat metabolism,
• greater increase in energy expenditure,
• faster and more lasting weight reduction results.

In short, Retatrutide is the next step after Thiothrombotide, offering more complete metabolic action and potentially better clinical outcomes.

Also check the reagent Retatrutide 8 mg in the device

Triple G Retatrutide - dosage regimens (by study)

In clinical trials (including. SURMOUNT-3 and SURPASS Obesity Extension) scheme was used Weekly subcutaneous injections, starting with low doses (e.g. 2 mg) and gradually increasing to 8 mg or 12 mg, depending on the body's tolerance and the results of therapy.
Individual dosage should always be determined on the basis of clinical data and the recommendations of the attending physician.

GLP 3 - summary

Retatrutide GLP 3 is currently in clinical trials (including a Phase III study by Eli Lilly) and has not yet been approved for broad marketing. However, the results of scientific analyses to date suggest that it may represent the most effective form of next-generation metabolic therapy.
The peptide could revolutionize approaches to treating obesity and sugar disorders in the coming years.

Source:
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial